|Jan 12, 2015||CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases|
|SEATTLE, Jan. 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced today the appointment of Alan K. Burnett, M.D., to serve as the strategic leader for myeloid development. Dr. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University and is highly regarded internationally for his work in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndr... |
|Jan 08, 2015||CTI BioPharma Announces 2015 Outlook and Recent Drug Portfolio Progress|
|SEATTLE, Jan. 8, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an overview of recent progress for its drug portfolio in addition to several anticipated key objectives for 2015.
"We ended a productive 2014 and have entered a promising 2015 stronger and more focused than we have been in recent years," said James A. Bianco, M.D., CTI BioPharma's President and Chief Executive Officer. "In the latter part of 2014, we entered into a global developm... |